The FDA Pharmacy Compounding Advisory Committee (PCAC) closed the two-day peptide session Friday July 24, 2026 with two more advisory wins and one narrow rejection. Semax, a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic, was recommended 8-5 for the Section 503A Bulks List for adult cerebral ischemia, migraine, and trigeminal neuralgia. Epitalon, a synthetic tetrapeptide nominated for insomnia and anti-aging, was recommended 7-4 for adult insomnia. Emideltide (delta sleep-inducing peptide, DSIP), a nonapeptide first isolated from rabbit brain in 1974 and nominated for insomnia and opioid withdrawal, was narrowly voted against, the sole rejection of the two-day session. STAT News framed the Day 2 outcome as 'FDA advisory panel narrowly rejects compounding of one peptide, backs two others.' FDA career-staff briefing documents released June 29-30 recommended against all three Day-2 peptides, citing insufficient evidence of effectiveness for Epitalon in insomnia and 'balancing of the criteria weighs against' Semax. The recommendations are advisory only.
The FDA Pharmacy Compounding Advisory Committee (PCAC) reconvenes Friday July 24, 2026 at 8:00 AM ET at FDA's White Oak Campus in Silver Spring, Maryland for Day 2 of the peptide review. Friday's schedule covers three peptides: DSIP/Emideltide (delta sleep-inducing peptide, a nonapeptide first isolated from rabbit brain in 1974 and nominated for sleep disorders and opioid withdrawal); Semax (a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic and nominated for cerebral ischemia, migraine, and trigeminal neuralgia); and Epitalon (a synthetic tetrapeptide nominated for insomnia and anti-aging applications). FDA career-staff briefing documents recommend against adding any of the three peptides to the Section 503A Bulks List. Panel composition (with at least seven of eight new members carrying peptide-industry ties per STAT News reporting) and Thursday's 8-6 BPC-157 and KPV votes suggest similar narrow majorities may recommend the Day-2 substances against career-staff positions. The Friday session closes at 3:50 PM ET. FDA rulemaking to implement any advisory recommendation would take approximately 6-18 months.
Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.
ASCO 2026 Day 2 in Chicago continued the meeting's peptide-and-targeted-conjugate oncology programming. Saturday May 30 brought the Immutep eftilagimod alfa survival pooled analysis and the ImPact Biotech padeliporfin VTP pancreatic data, alongside the Bicycle Therapeutics zelenectide pevedotin dose-optimization poster (Abstract 4567, May 31) approaching. The meeting's heaviest peptide-mechanism day is Monday June 1: Bicycle Duravelo-2 zelenectide pevedotin + pembrolizumab oral presentation in 1L urothelial (Abstract 4516, 8:30 AM CT); Mayo Clinic TPIV200 folate-receptor peptide vaccine in triple-negative breast cancer (Abstract 536, 1:30 PM CT); Telix ProstACT PSMA radioligand Phase 3 Part 1; Sapience lucicebtide GBM poster. The Corbus CRB-701 Nectin-4 ADC data (42.9% OPSCC / 34.4% cervical) landed Friday May 29. The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — remain the densest peptide-adjacent oncology competition, with the bulk of definitive readouts concentrated in the meeting's back half through June 2.